semaglutide cvot trial Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes | Cardiovascular Diabetology Cardiovascular risk reduction with once-weekly
Description
For a market most Western pharma teams still treat as secondary, that's a striking number
Ed Timm, CEO of a local pharmaceutical company, shares concerns about the mass production of compounded Semaglutide, citing past incidents of contaminated injectable steroids causing severe health issues
To view or add a comment, sign in Ophthopedia Update:Comment on Macular OCTA Biomarkers Predict Regional Retinal Nonperfusion Patterns on Ultra-Widefield Angiography in Diabetes: The recent study by Kakihara et al
Stewart, J., BPharm
Y.ReimannF.GribbleF
